IP Library Granted Patent US 8,084,228
Granted Patent B2
US 8,084,228 · App. 12/087,435 · Granted Dec 27, 2011

Nogo-B receptor antagonists

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,084,228
App. No.
12/087,435
Granted
Dec 27, 2011
Kind
B2
Abstract

Nogo-B receptors bind to Nogo-B and mediate its biological function. We have discovered that Nogo-B receptor is a component of endothelial cells, and is highly expressed in intact blood vessels. The present invention provides compositions comprising the Nogo-B receptor and fragments and fusion proteins thereof. The present invention also relates to nucleic acids encoding the Nogo-B receptor and fragments and fusion proteins thereof, as well as vectors and cells comprising such nucleic acids. The present invention also relates to antibodies specific for the Nogo-B receptor and fragments and fusion proteins thereof. The present invention also provides methods for preventing, detecting and treating Nogo-B receptor-related diseases, disorders and conditions.

Claims (12)

1. A composition comprising a fragment of a Nogo-B receptor that inhibits a biological activity of a Nogo-B receptor, wherein said fragment consists of residues 52-116 of SEQ ID NO: 1.

2. A fusion protein comprising a fragment of Nogo-B receptor and a heterologous protein component, wherein said fragment consists of residues 52-116 of SEQ ID NO: 1.

3. A nucleic acid molecule comprising a nucleotide sequence encoding the fusion protein of claim 2 .

4. A vector comprising the nucleic acid molecule of claim 3 .

5. A host cell comprising the nucleic acid molecule of claim 3 or the vector of claim 4 .

6. A method for producing a fusion protein, wherein said fusion protein comprises a fragment of Nogo-B receptor consisting of residues 52-116 of SEQ ID NO: 1, said method comprising culturing the host cell of claim 5 under suitable conditions in media so that the host cell produces the fusion protein and isolating the fusion protein.

7. A composition comprising a fragment of a Nogo-B receptor that inhibits a biological activity of a Nogo-B receptor, wherein said fragment consists of the amino acid sequence of SEQ ID NO: 14, SEQ ID NO: 16, or SEQ ID NO: 18.

8. A fusion protein comprising a fragment of Nogo-B receptor and a heterologous protein component, wherein said fragment consists of the amino acid sequence of SEQ ID NO: 14, SEQ ID NO: 16, or SEQ ID NO: 18.

9. A nucleic acid molecule comprising a nucleotide sequence encoding the fusion protein of claim 8 .

10. A vector comprising the nucleic acid molecule of claim 9 .

11. A host cell comprising the nucleic acid molecule of claim 9 or the vector of claim 10 .

12. A method for producing a fusion protein, wherein said fusion protein comprises a fragment of Nogo-B receptor consisting of the amino acid sequence of SEQ ID NO: 14, SEQ ID NO: 16, or SEQ ID NO: 18, said method comprising culturing the host cell of claim 11 under suitable conditions in media so that the host cell produces the fusion protein and isolating the fusion protein.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2011
From: SESSA, WILLIAM C.; MIAO, QING
To: YALE UNIVERSITY
Reel/Frame 027265/0280 →
CONFIRMATORY LICENSE Recorded Aug 20, 2010
From: YALE UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024865/0679 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 6, 2008
From: SESSA, WILLIAM C.; MIAO, QING
To: YALE UNIVERSITY
Reel/Frame 021641/0421 →